| CEO Kwunho Jeong, Introduces the 'Maven Clinical Cloud' and Other Solutions at KIC 2023
Kwunho Jeong, CEO of JNPMEDI, delivering a presentation during the DCT session at KIC 2023
JNPMEDI announced on the 13th that they showcased their Distributed Clinical Trial (DCT) solutions based on a data platform at the ‘2023 KoNECT International Conference’ (KIC2023).
The 9th annual KIC2023, co-hosted by the National Clinical Trial Support Foundation, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, is the largest clinical trial conference in Asia. This event brought together over 1,500 new drug development experts from approximately 450 companies and institutions, including domestic and international biotech specialists, pharmaceutical developers, clinical researchers, regulatory agencies, and CRO clinical experts.
JNPMEDI participated in the event to strengthen its network with industry experts. Through their exhibition booth, they showcased the 'Maven Clinical Cloud' platform and a variety of clinical trial services.
Kwunho Jeong, CEO of JNPMEDI, chaired a special session on DCT and Smart Clinical Trials (SCT) during the event. He discussed the current status of digital therapeutics development, the application of new technologies utilizing big data and artificial intelligence (AI), and introduced DCT and futuristic clinical trials while proposing effective implementation strategies.
JNPMEDI aims to expand its outreach further. They plan to actively seek opportunities for collaboration with overseas partners while increasing their global influence through active international engagements. This strategy involves strengthening their research and development capabilities for their solutions by understanding the latest trends in global drug development and regulations. They aim to explore business models directly connected to worldwide healthcare markets, enhancing their brand competitiveness.
Jeong expressed delight in participating in an international event that acknowledges the value of their platforms and services, providing an opportunity to discuss the present and future of the clinical trial field. He emphasized their commitment to amplifying the potential of cutting-edge DCT solutions driving digital transformations, consolidating their position as a leading company driving innovation in the global clinical trial industry.
| CEO Kwunho Jeong, Introduces the 'Maven Clinical Cloud' and Other Solutions at KIC 2023
Kwunho Jeong, CEO of JNPMEDI, delivering a presentation during the DCT session at KIC 2023
JNPMEDI announced on the 13th that they showcased their Distributed Clinical Trial (DCT) solutions based on a data platform at the ‘2023 KoNECT International Conference’ (KIC2023).
The 9th annual KIC2023, co-hosted by the National Clinical Trial Support Foundation, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, is the largest clinical trial conference in Asia. This event brought together over 1,500 new drug development experts from approximately 450 companies and institutions, including domestic and international biotech specialists, pharmaceutical developers, clinical researchers, regulatory agencies, and CRO clinical experts.
JNPMEDI participated in the event to strengthen its network with industry experts. Through their exhibition booth, they showcased the 'Maven Clinical Cloud' platform and a variety of clinical trial services.
Kwunho Jeong, CEO of JNPMEDI, chaired a special session on DCT and Smart Clinical Trials (SCT) during the event. He discussed the current status of digital therapeutics development, the application of new technologies utilizing big data and artificial intelligence (AI), and introduced DCT and futuristic clinical trials while proposing effective implementation strategies.
JNPMEDI aims to expand its outreach further. They plan to actively seek opportunities for collaboration with overseas partners while increasing their global influence through active international engagements. This strategy involves strengthening their research and development capabilities for their solutions by understanding the latest trends in global drug development and regulations. They aim to explore business models directly connected to worldwide healthcare markets, enhancing their brand competitiveness.
Jeong expressed delight in participating in an international event that acknowledges the value of their platforms and services, providing an opportunity to discuss the present and future of the clinical trial field. He emphasized their commitment to amplifying the potential of cutting-edge DCT solutions driving digital transformations, consolidating their position as a leading company driving innovation in the global clinical trial industry.